Anteris Technologies

Last week Dr. Ole De Backer presented a DurAVR® THV case recording to a packed room at New York Valves! The case from Rigshospitalet in Copenhagen showcased DurAVR® THV’s paradigm-shifting hemodynamic performance with a predictable and familiar balloon-expandable delivery. Unlike…

Does LV mass regression post-TAVR correlate with clear differences in patient outcomes? In the 3rd and final episode of our 3-part webinar series, Studying the Clinical Impact of Restoring Native Flow with DurAVR® THV, panelists Drs. Brian Lindman, Martin Leon, Jeffrey Popma, and…

This week we hosted Heart Teams from across the globe in New York City alongside the New York Valves conference for the global investigator meeting of the PARADIGM Trial. The alignment and enthusiasm from investigators and research teams have set the stage for what promises to be…

We are excited to share Episode 2 of our 3-part webinar series, Studying the Clinical Impact of Restoring Native Flow with DurAVR® THV. Building on the foundation laid out in Episode 1, this session dives deeper into the upstream and downstream impacts of restoring laminar flow…

DurAVR® THV is a novel biomimetic valve that aims to restore native flow in patients with aortic stenosis. In our latest webcast, a panel of experts provides insight on this new treatment option: tctmd.com/Studying-the-C…

We are excited to launch our new 3-part webinar series: Studying the Clinical Impact of Restoring Native Flow With Biomimetic DurAVR® THV. We’ve partnered with @crfheart to move the conversation forward and explore this topic that is critical for the future of aortic stenosis…

🎥 Coming soon! We just wrapped up the filming of our upcoming webinar at the CRF studio with Drs. Martin Leon, Yoshi Kaneko, Jeff Popma, and Brian Lindman. Stay tuned for our 3-part webinar series about the importance of restoring physiologic flow and implications for patient…

DurAVR® THV was featured in a presentation yesterday at #EuroPCR at the “Innovation to address unmet clinical needs in transcatheter therapies” session. Dr. Hendrik Treede presented present and future TAVI innovations, including DurAVR® THV, a new class of TAVR (biomimetic).…

Today at #EuroPCR Dr. Gintautas Bieliauskas presented data on the biomimetic DurAVR® Transcatheter Heart Valve (THV), including 1-year clinical results. In addition to demonstrating restoration of physiologic laminar flow on cardiac MRI... ✅ DurAVR® THV demonstrated a…

Join Dr. Gintautas Bieliauskas tomorrow at 8:30 a.m. for a clinical data update on the biomimetic DurAVR® Transcatheter Heart Valve, a new class of TAVR designed to mimic the performance of a healthy aortic valve. We look forward to seeing you there! #TAVI #TAVR #aorticstenosis…

Healthy, physiologic blood flow through the aortic valve is mostly laminar (straight). Flow patterns are measured on a spectrum and should be quantified in order to compare to healthy flow. In this video, Dr. João Cavalcante describes 2 key metrics cardiac imagers use to assess…

Attending EuroPCR? Tune in to the innovation session presentation on Wednesday, May 21 by Dr. Gintautas Bieliauskas to learn about the impact of DurAVR® THV’s biomimetic design on flow dynamics and see the latest clinical data from this new class of TAVR! #TAVI #TAVR…

DurAVR® THV is a first-in-class #biomimetic heart valve. Listen to this video from Dr. @chrismeduri to learn what biomimetic valve design means and what impact designing valves to mimic textbook healthy aortic valves might have on patient outcomes. #TAVR #TAVI #aorticstenosis…

🎉 100 patients milestone! We are extremely excited to announce that over 100 patients have now been treated with the DurAVR® Transcatheter Heart Valve (THV)! Each heart on our Heart Wall represents a patient who has been treated with DurAVR® THV. Every day our growing Heart Wall…

This Doctors’ Day we want to extend a heartfelt thank you to all the physicians who have helped us move the conversation forward and redefine success in aortic stenosis treatment—from our implanting physicians and heart teams to those who have helped with product development and…

We are excited to share 1-year data from DurAVR® THV clinical experience, presented by Rishi Puri at Sydney Valves! One-year Results Highlights: ✅ DurAVR® THV demonstrated a favorable hemodynamic profile sustained to one-year, with an Effective Orifice Area (EOA) of 2.1 + 0.2…

Tomorrow we are presenting new DurAVR® THV clinical data at Sydney Valves! Join Dr. Rishi Puri in Grand Ballroom 1 at 10:30 a.m. Not attending? Sign up here for clinical data updates: bit.ly/3XUk9LF #TAVI #TAVR #aorticstenosis #SydneyValves DurAVR® INVESTIGATIONAL…

We are excited to share new data at Sydney Valves next week! On Friday, March 21 Dr. Rishi Puri will present in the Late-Breaking Clinical Trial session with new data from DurAVR® THV clinical experience. Not attending? Sign up here for clinical data updates…

At the CRT conference this week, Dr. Isaac George presented about advances in leaflet technologies used in replacement heart valves and featured the ADAPT® tissue technology from Anteris. ADAPT®-treated tissue has been clinically proven to be calcium-free through 10 years of…

In this fireside chat at the TD Cowen Healthcare Conference, Anteris CEO Wayne Paterson discusses the history of the company and how we sought to address unmet needs in aortic stenosis patients. Anteris created a first-in-class biomimetic TAVR valve by asking different questions…